Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter

Journal of Molecular Medicine

Volumn 94, Issue 12, 2016, Pages 1397-1409

  Banerjee, Poulomi ^a   Surendran, Harshini ^a   Chowdhury, Debabani Roy ^c   Prabhakar, Karthik ^b   Pal, Rajarshi ^a  

^a MANIPAL UNIVERSITY   (India)

^b MANIPAL HOSPITAL   (India)

^c CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

AMPK; Diabetes; E cadherin; Epithelial mesenchymal transition; ERK; Metformin; Methylation

Indexed keywords

CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; GELATINASE A; GELATINASE B; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN ZO1; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VIMENTIN; ANTIDIABETIC AGENT; CADHERIN; CDH1 PROTEIN, HUMAN; HISTONE; HISTONE DEACETYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SNAI1 PROTEIN, HUMAN;

A549 CELL LINE; ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL SHAPE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DNA METHYLATION; ENZYME ACTIVATION; ENZYME ACTIVITY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; MALE; MDA MB 231 CELL LINE; MESENCHYME CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PROMOTER REGION; SIGNAL TRANSDUCTION; SPINDLE CELL; STROMA CELL; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT; UPREGULATION; BINDING SITE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

AGED; AMP-ACTIVATED PROTEIN KINASES; BASE SEQUENCE; BINDING SITES; CADHERINS; CELL LINE, TUMOR; DIABETES MELLITUS, TYPE 2; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HISTONES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; SNAIL FAMILY TRANSCRIPTION FACTORS;

EID: 84982311120     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-016-1455-7     Document Type: Article

References (38)

1. Hawley S, Gadalla AE, Olsen GS, Grahame Hardie D (2002) The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51(8):2420–2425
2. Libby G, Donnelly LA, Donnan PT (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620–1625
3. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67:10804–10812
4. Plews RL, Mohd Yusof A, Wang C, Saji M, Zhang X, Chen CS, Ringel MD, Phay JE (2015) A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab 100(5):E748–E756
5. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA (2010) Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 9(22):4461–4468
6. Sebolt-Leopold JS, English JM (2006) Mechanisms of drug inhibition of signalling molecules. Nature 441:457–462
7. Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937–947
8. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26(22):3291–3310
9. De Herreros AG, Peiro S, Nassour M, Savagner P (2010) Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J Mammary Gland Biol Neoplasia 15(2):135–147
10. Pećina-Slaus N (2003) Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 3:17
11. Jeanes A, Gottardi CJ, Yap AS (2003) Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 27(55):6920–6929
12. Dong C, Wu Y, Yao J, Wang Y, Yu Y, Rychahou PG, Evers BM, Zhou BP (2012) G9a interacts with snail and is critical for snail-mediated E-cadherin repression in human breast cancer. J Clin Invest 122(4):1469–1486
13. Banerjee P, Venkatachalam S, Mamidi MK, Bhonde R, Shankar K, Pal R (2015) Vitiligo patient-derived keratinocytes exhibit characteristics of normal wound healing via epithelial to mesenchymal transition. Exp Dermatol 24(5):391–393
14. Han W, Cauchi S, Herman JG, Spivack SD (2006) DNA methylation mapping by tag modified bisulfite genomic sequencing. Anal Biochem 355(1):50–61
15. Carpenter PM, Al-kuran RA, Theuer CP (2002) Paranuclear E-cadherin in gastric adenocarcinoma. Am J Clin Pathol 118(6):887–894
16. Chen C, Liu SS, Ip S, Wong LC, Ng TY, Ngan HYS (2003) E-cadherin expression is silenced by DNA methylation in cervical cancer cell lines and tumours. Eur J Cancer 39(4):517–523
17. Chao YL, Shepard CR, Wells A (2010) Breast carcinoma cells Re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 9:179
18. Howard EW, Camm KD, Wong YC, Wang XH (2008) E-cadherin upregulation as a therapeutic goal in cancer treatment. Mini Rev Med Chem 8(5):496–518
19. Lin YC, Lee YC, Li LH, Cheng CJ, Yang RB (2014) Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition. J Cell Sci 127:85–100
20. Austin P, Freeman SA, Gray C (2013) The invasion inhibitor sarasinoside A1 reverses mesenchymal tumor transformation in an E-cadherin-independent manner. Mol Cancer Res 11(5):530–540
21. Banerjee P, Dutta S, Pal R (2015) Dysregulation of Wnt-signaling and a candidate set of miRNAs underlie the effect of metformin on neural crest cell development. Stem Cells. doi:10.1002/stem.2245
22. Buijs JT, Rentsch C, van der Horst G (2007) BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 171(3):1047–1057
23. Yan W, Cao QJ, Arenas RB, Bentley B, Shao R (2010) GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem 285(18):14042–14051
24. Sheng W, Wang G, La Pierre DP (2006) Versican mediates mesenchymal – epithelial transition. Mol Biol Cell 17(4):2009–2020
25. Sarkar S, Abujamra AL, Loew JE, Forman LW, Perrine SP, Faller DV (2011) Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res 31(9):2723–2732
26. Peinado H, Ballestar E, Esteller M, Cano A (2004) Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 24(1):306–319
27. Law ME, Corsino PE, Jahn SC, Davis BJ, Chen S, Patel B, Pham K, Lu J, Sheppard B, Norgaard P et al (2013) Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. Oncogene 32(10):1316–1329
28. Conacci-Sorrell M, Simcha I, Ben-Yedidia T, Blechman J, Savagner P, Ben-Ze’ev A (2003) Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of β-catenin signaling, slug, and MAPK. J Cell Biol 163(4):847–857
29. Das S, Becker BN, Hoffmann FM, Mertz JE (2009) Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the rho pathway. BMC Cell Biol 10:94
30. Motoshima H, Goldstein BJ, Igata M, Araki E (2006) AMPK and cell proliferation – AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574:63–71
31. Lee JH, Kim JH, Kim JS, Chang JW, Kim SB, Park JS, Lee SK (2013) AMP-activated protein kinase inhibits TGF-β-, angiotensin II-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition. Am J Physiol Renal Physiol 304(6):F686–F697
32. Kim J, Yoon M, Choi S (2001) Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1- and epidermal growth effects of stimulation of AMP-activated protein kinase on insulin- like growth factor 1- and epidermal growth factor-dependent. J Biol Chem 276(22):19102–19110
33. Kim M-J, Park I-J, Yun H (2010) AMP-activated protein kinase antagonizes pro-apoptotic extracellular signal-regulated kinase activation by inducing dual-specificity protein phosphatases in response to glucose deprivation in HCT116 carcinoma. J Biol Chem 285(19):14617–14627
34. Kim H, Kim M, Ju E, Yang Y, Lee M, Lim J (2012) Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem Pharmacol 83(3):385–394
35. Cerezo M, Tichet M, Abbe P (2013) Metformin blocks melanoma invasion and metastasis development in a AMPK / p53-dependent manner. Mol Cancer Ther 12(8):1605–1615
36. Luo Q, Hu D, Hu S, Yan M, Sun Z, Chen F (2012) In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer 12(1):517
37. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V (2011) Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin. Neoplasia 13(5):483–491
38. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis P (2013) Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 24(9):469–480